Alpha Cognition Inc
ACOG
Rank in Stocks
#20038
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Share Price
$8.75
Market Cap
$135.82M
Change (1 day)
2.88%
Change (1 year)
73.86%
Country
US
Trade Alpha Cognition Inc (ACOG)
Category
Healthcare
Earnings for Alpha Cognition Inc (ACOG)
Earnings in Jun 2026 TTM: 0.00
According to Alpha Cognition Inc latest financial reports the company's current earnings are 0.00. In 2022 the company made an earning of $-12.11M, an increase over its 2021 earnings that were of $-19.55M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Alpha Cognition Inc from 2018 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2023 | $-13.77M | 13.68% |
| 2022 | $-12.11M | -38.02% |
| 2021 | $-19.55M | 237.90% |
| 2020 | $-5.78M | -12.45% |
| 2019 | $-6.61M | 20,254.71% |
| 2018 | $-32.46K | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| - | - |
CH
|
|
| $1.95B | - |
NL
|
